Sermorelin vs CJC-1295
GHRH Analog (GRF 1-29) · Modified GHRH Analog
Here is how these two compounds compare, based on published research, not marketing claims.
Sermorelin
The gentlest way to nudge the body's own growth hormone production.
CJC-1295
A longer-lasting version that needs fewer shots.
Sermorelin
328 studies
20 human trials
Not FDA-Approved
CJC-1295
27 studies
2 human trials
Not FDA-Approved
What it does
Sermorelin
Copies the working portion of the body's natural growth hormone signal directly, with no modifications added: just the first 29 amino acids of GHRH out of 44 in the full molecule. The original peptide in this class, and still the closest thing to what the brain actually produces. Half-life is short by design, on the order of 10 to 15 minutes, the same as native GHRH.
CJC-1295
Stretches a growth hormone signal that normally lasts minutes into one that lasts days. A small chemistry change attaches the molecule to albumin, a protein already circulating in the blood, which protects it from being broken down. In the published research, that translates to a half-life of roughly six to eight days, compared with minutes for the body's native GHRH.
How it works
Sermorelin
A lab-made copy of the first 29 amino acids of the body's natural growth hormone signal. It matches what the body already produces, which is why people call it the 'closest to natural' option.
CJC-1295
A modified version of the body's natural growth hormone signal. The modification makes it resist breakdown, so it stays active longer in the bloodstream.
How often
Sermorelin
In studies and historical clinical use as Geref, sermorelin was given as a daily subcutaneous injection, typically in the evening, which clinical literature describes as aligned with the body's natural overnight growth hormone pulse. The active window is brief, roughly ten minutes.
CJC-1295
In Phase I/II trials, CJC-1295 with DAC was given as a subcutaneous injection once or twice per week. The DAC modification (drug affinity complex) extends the active window to several days, which is what allows the once-or-twice-weekly schedule rather than daily injection.
How strong
Sermorelin
Mild. A modest increase over the body's natural growth hormone release, not an override.
CJC-1295
Stronger and more sustained. A bigger growth hormone pulse that lasts longer.
Main tradeoff
Sermorelin
Daily injections. Subtler effects. Some people plateau after several months.
CJC-1295
Less pulsatile than the body's natural rhythm. Side effects, if they happen, stick around longer because the drug stays active longer.
Best for
Sermorelin
- Beginners to peptides
- People who want the most 'natural' approach
- Anyone prioritizing a gentle, long-term effect over peak results
CJC-1295
- People who want fewer injections per week
- People who've plateaued on Sermorelin
- Anyone planning to stack with Ipamorelin (a popular combination because the two work through different receptors and amplify each other)
How to choose
A good fit for Sermorelin
- New to GH peptides
- Prioritizing a natural GH rhythm over peak effect
- Research contexts using daily subcutaneous injection schedules
- Research focused on a gentle, conservative GHRH analog starting profile
A good fit for CJC-1295
- Seeking fewer injections per week
- Seeking a stronger and more sustained effect
- Having plateaued on Sermorelin
- Planning to stack with Ipamorelin
Consider both across time
Many protocols begin with Sermorelin and transition to CJC-1295 after a plateau. This is a common progression pattern in the research literature, not a binary choice.
Dosing should be determined by a qualified physician who can evaluate individual circumstances. PSI does not provide personalized dosing guidance.
Official dosing references
- DailyMed(NIH drug labels)
- ClinicalTrials.gov
- PubMed
For readers who want the biology: here is the pathway each compound uses to signal the body. This section is optional. The comparison above covers the practical differences.
▶See the biology
- GHRH Receptor
- GHRH Receptor activates Adenylyl Cyclase
- Adenylyl Cyclase connects to cAMP Signaling
- cAMP Signaling connects to GH Transcription
- GH Transcription connects to Growth Hormone Release; Anterior Pituitary connects to Growth Hormone Release
- Growth Hormone Release connects to IGF-1 Elevation
- GHRH Receptor activates GHRH Signaling
- GHRH Signaling connects to Anterior Pituitary
Sermorelin binds the GHRH receptor on the pituitary (the body's natural 'release growth hormone' signal) and tells it to fire.
CJC-1295 binds the same receptor but with a modification that keeps it active for days instead of minutes.
Research Evidence
Sermorelin has the larger research base: decades of clinical use including prior FDA approval for diagnostic work in children. CJC-1295 has narrower but solid evidence, mostly focused on how the drug behaves in the body rather than long-term outcomes. Sermorelin's evidence covers human outcomes across populations and decades; CJC-1295's evidence is mostly pharmacokinetic and from earlier-phase human trials. For research where outcome data depth matters, Sermorelin has the stronger position. For research focused on dosing convenience, CJC-1295 has solid grounding.
- 1.
For research on growth hormone patterns that match the body's natural rhythm, Sermorelin is the better fit. Its short action lets the body's own feedback system regulate growth hormone levels, something the longer-acting CJC-1295 bypasses.
- 2.
For research requiring sustained growth hormone elevation with fewer injections, CJC-1295 with DAC offers the longest-duration option available among growth hormone-releasing peptides.
- 3.
For research prioritizing clinical safety confidence and regulatory precedent, Sermorelin has the advantage of prior FDA approval and decades of clinical use.
- 4.
For research comparing short-pulse versus sustained growth hormone stimulation, using both compounds (either together or head-to-head) makes an informative experimental design.
Key Limitations
- •Sermorelin's commercial availability has been limited since manufacturing discontinuation by its original producer.
- •CJC-1295 has never achieved FDA approval, its development did not progress beyond Phase II.
- •Neither compound has completed modern Phase III trials for therapeutic GH deficiency endpoints.
- •The clinical significance of pulsatile vs. sustained GH stimulation patterns is not resolved in the literature.
- •Both compounds are used in clinical contexts off-label, making standardized efficacy data difficult to aggregate.
Community Discussion
PSI monitors discussions across peptide research and biohacking communities. These are reported experiences, not clinical evidence.
Sermorelin
"Sermorelin is the safest way to boost growth hormone naturally"
Plausible but unproven
"It improves sleep quality dramatically"
Plausible but unproven
"It stopped working after a few months"
Plausible but unproven
CJC-1295
"CJC-1295 with DAC gives you sustained growth hormone elevation for days"
Supported by published data
"Stacking CJC-1295 with ipamorelin is the gold standard for GH optimization"
Plausible but unproven
"It made me retain water and feel bloated"
Supported by published data
Safety Comparison
Sermorelin has the strongest safety track record of any growth hormone-releasing peptide: thousands of patient-years of data from pediatric and adult use when it was FDA-approved. CJC-1295 has smaller safety datasets from Phase I and Phase II trials. The longer-acting nature of CJC-1295 raises theoretical questions about sustained growth hormone exposure that are not a concern with Sermorelin's short pulses.
Sermorelin
The most extensively studied growth hormone-releasing peptide in clinical settings. Approved by the FDA as Geref for diagnostic use. Studies in children and adults have established a favorable safety profile with few serious adverse events. Common side effects: injection site reactions, flushing, and headache.
CJC-1295
Early human trials show generally favorable tolerability. The with-DAC version keeps growth hormone elevated for days rather than hours, which raises theoretical questions about prolonged exposure that don't apply to Sermorelin's short pulses. Less long-term safety data than Sermorelin.
What the Research Suggests
Sermorelin and CJC-1295 represent two different design choices. Sermorelin aims to copy the body's natural growth hormone rhythm: short, steady pulses that match what healthy pituitaries produce on their own. CJC-1295 (with DAC) trades that natural pattern for convenience. A single injection lasts days instead of hours, reducing injection frequency but sustaining growth hormone levels far longer than the body would on its own. Sermorelin has the stronger clinical track record and the regulatory history. CJC-1295 offers the advantage of less frequent dosing, but with a smaller human evidence base and theoretical questions about sustained growth hormone exposure that don't apply to Sermorelin. The choice depends on whether the research priority is clinical precedent or sustained effect.